title: Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms.
abstract: We previously found that gender influenced the JAK2 V617F allele burden, but it is unknown whether this gender difference in molecular epidemiology influences complications in the myeloproliferative neoplasms (MPNs). Historically, vascular complications represented the most common cause of mortality in polycythemia vera and essential thrombocytosis and contributed to morbidity in primary myelofibrosis. To determine the influence of gender on vascular complications, we retrospectively analyzed associations between gender and vascular complications. Despite their younger age, less prevalent dyslipidemia or smoking history, lower white blood counts, and lower JAK2 V617F allele burden, women had higher rates of abdominal venous thrombosis and comparable rates of all vascular complications. Vascular risk is currently not easily stratified by MPN-disease burden or traditional risk factors. Our analysis contributes to growing literature emphasizing gender differences in the MPN and further supports the important impact of individual and host variation on MPN clinical manifestations, and especially vascular risk.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
authors.forename: Brady L
authors.initials: BL
authors.lastname: Stein
authors.forename: Alfred
authors.initials: A
authors.lastname: Rademaker
authors.forename: Jerry L
authors.initials: JL
authors.lastname: Spivak
authors.forename: Alison R
authors.initials: AR
authors.lastname: Moliterno
references.citation: Blood. 2007 Mar 15;109(6):2310-3
references.pmid: 17110452
references.citation: J Thromb Thrombolysis. 2010 May;29(4):489-96
references.pmid: 19536458
references.citation: Circulation. 2010 Feb 23;121(7):948-54
references.pmid: 20177011
references.citation: Blood. 2010 Aug 26;116(8):1205-10; quiz 1387
references.pmid: 20508163
references.citation: Semin Hematol. 1986 Apr;23(2):132-43
references.pmid: 3704665
references.citation: Lancet. 2006 Jul 29;368(9533):371-8
references.pmid: 16876665
references.citation: J Clin Oncol. 1999 Sep;17(9):2954-70
references.pmid: 10561375
references.citation: JAMA. 2010 Jun 23;303(24):2513-8
references.pmid: 20571018
references.citation: JAMA. 1974 Jan 28;227(4):424-6
references.pmid: 4859680
references.citation: Semin Hematol. 1997 Jan;34(1):29-39
references.pmid: 9025160
references.citation: Blood. 2008 Jul 1;112(1):45-52
references.pmid: 18443215
references.citation: Thromb Res. 2011 Sep;128(3):233-6
references.pmid: 21497883
references.citation: Blood. 2010 Aug 19;116(7):1051-5
references.pmid: 20479281
references.citation: Acta Med Scand. 1950;138(3):179-87
references.pmid: 14782860
references.citation: Hepatology. 2006 Dec;44(6):1528-34
references.pmid: 17133457
references.citation: J Thromb Haemost. 2007 Jan;5(1):55-61
references.pmid: 17059429
references.citation: N Engl J Med. 2004 Jan 8;350(2):114-24
references.pmid: 14711910
references.citation: Neurology. 2007 Nov 13;69(20):1898-904
references.pmid: 17581944
references.citation: Thromb Haemost. 2006 Sep;96(3):267-73
references.pmid: 16953266
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2224-32
references.pmid: 15710945
references.citation: Am J Med. 2004 Nov 15;117(10):755-61
references.pmid: 15541325
references.citation: Blood. 2010 Jan 28;115(4):778-82
references.pmid: 19965680
references.citation: Haematologica. 2010 Jul;95(7):1090-7
references.pmid: 20133898
references.citation: Blood. 2006 Dec 1;108(12):3913-5
references.pmid: 16912229
references.citation: Leukemia. 2007 Sep;21(9):1952-9
references.pmid: 17625606
references.citation: Blood. 2008 May 15;111(10):4922-9
references.pmid: 18250227
references.citation: Leuk Res. 2007 Jun;31(6):737-40
references.pmid: 17210175